(AME) Ametek - Overview
Stock: Instruments, Sensors, Power, Connectors, Motors
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.68% |
| Yield on Cost 5y | 1.07% |
| Yield CAGR 5y | 11.58% |
| Payout Consistency | 94.5% |
| Payout Ratio | 17.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 20.0% |
| Relative Tail Risk | -9.25% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.01 |
| Alpha | 16.26 |
| Character TTM | |
|---|---|
| Beta | 0.795 |
| Beta Downside | 0.843 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.04% |
| CAGR/Max DD | 0.78 |
Description: AME Ametek January 28, 2026
AMETEK (NYSE:AME) operates two primary divisions: Electronic Instruments Group (EIG) and Electromechanical Group (EMG). EIG supplies advanced measurement and control hardware to process, aerospace, power, and industrial markets, covering applications from oil-and-gas analytics to semiconductor test equipment and UAV sensors. EMG focuses on engineered medical components, specialty metals, thermal-management systems, precision motion-control products, and a network of aviation MRO facilities, serving sectors ranging from healthcare to defense and commercial appliances.
In FY 2023 the company reported $6.1 billion in revenue, a 5% YoY increase, with an adjusted operating margin of 14% and a free-cash-flow conversion of 78%. The order backlog stood at $2.3 billion, indicating roughly 12 months of visible demand. Key macro drivers include a 6% rise in U.S. defense spending (supporting aerospace and MRO sales), a 5% CAGR in global industrial automation (benefiting EMG’s motion-control and thermal-management lines), and a sustained semiconductor equipment shortage that underpins demand for EIG’s test-and-measurement solutions.
For a data-rich, quantitative follow-up, you might explore ValueRay’s analyst model on AME to see how these fundamentals translate into projected valuation scenarios.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 1.48b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -4.51 > 1.0 |
| NWC/Revenue: 2.39% < 20% (prev 7.27%; Δ -4.87% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1.22b > Net Income 1.48b |
| Net Debt (1.83b) to EBITDA (2.09b): 0.87 < 3 |
| Current Ratio: 1.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (230.4m) vs 12m ago -0.76% < -2% |
| Gross Margin: 36.28% > 18% (prev 0.36%; Δ 3592 % > 0.5%) |
| Asset Turnover: 48.22% > 50% (prev 47.44%; Δ 0.78% > 0%) |
| Interest Coverage Ratio: 17.02 > 6 (EBITDA TTM 2.09b / Interest Expense TTM 81.3m) |
Altman Z'' 5.15
| A: 0.01 (Total Current Assets 3.02b - Total Current Liabilities 2.84b) / Total Assets 16.07b |
| B: 0.74 (Retained Earnings 11.92b / Total Assets 16.07b) |
| C: 0.09 (EBIT TTM 1.38b / Avg Total Assets 15.35b) |
| D: 1.95 (Book Value of Equity 10.63b / Total Liabilities 5.44b) |
| Altman-Z'' Score: 5.15 = AAA |
Beneish M -2.90
| DSRI: 1.11 (Receivables 1.12b/948.8m, Revenue 7.40b/6.94b) |
| GMI: 0.98 (GM 36.28% / 35.68%) |
| AQI: 0.99 (AQ_t 0.74 / AQ_t-1 0.75) |
| SGI: 1.07 (Revenue 7.40b / 6.94b) |
| TATA: 0.02 (NI 1.48b - CFO 1.22b) / TA 16.07b) |
| Beneish M-Score: -2.90 (Cap -4..+1) = A |
What is the price of AME shares?
Over the past week, the price has changed by +3.54%, over one month by +8.29%, over three months by +17.75% and over the past year by +27.65%.
Is AME a buy, sell or hold?
- StrongBuy: 10
- Buy: 2
- Hold: 5
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the AME price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 248.3 | 7.1% |
| Analysts Target Price | 248.3 | 7.1% |
| ValueRay Target Price | 273.8 | 18.1% |
AME Fundamental Data Overview February 07, 2026
P/E Forward = 28.6533
P/S = 7.1707
P/B = 4.9345
P/EG = 2.8622
Revenue TTM = 7.40b USD
EBIT TTM = 1.38b USD
EBITDA TTM = 2.09b USD
Long Term Debt = 1.07b USD (from longTermDebt, last quarter)
Short Term Debt = 1.21b USD (from shortTermDebt, last quarter)
Debt = 2.28b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.83b USD (from netDebt column, last quarter)
Enterprise Value = 54.90b USD (53.07b + Debt 2.28b - CCE 458.0m)
Interest Coverage Ratio = 17.02 (Ebit TTM 1.38b / Interest Expense TTM 81.3m)
EV/FCF = 47.98x (Enterprise Value 54.90b / FCF TTM 1.14b)
FCF Yield = 2.08% (FCF TTM 1.14b / Enterprise Value 54.90b)
FCF Margin = 15.46% (FCF TTM 1.14b / Revenue TTM 7.40b)
Net Margin = 20.00% (Net Income TTM 1.48b / Revenue TTM 7.40b)
Gross Margin = 36.28% ((Revenue TTM 7.40b - Cost of Revenue TTM 4.72b) / Revenue TTM)
Gross Margin QoQ = 36.93% (prev 36.25%)
Tobins Q-Ratio = 3.42 (Enterprise Value 54.90b / Total Assets 16.07b)
Interest Expense / Debt = 1.00% (Interest Expense 22.9m / Debt 2.28b)
Taxrate = 15.90% (75.4m / 474.0m)
NOPAT = 1.16b (EBIT 1.38b * (1 - 15.90%))
Current Ratio = 1.06 (Total Current Assets 3.02b / Total Current Liabilities 2.84b)
Debt / Equity = 0.21 (Debt 2.28b / totalStockholderEquity, last quarter 10.63b)
Debt / EBITDA = 0.87 (Net Debt 1.83b / EBITDA 2.09b)
Debt / FCF = 1.60 (Net Debt 1.83b / FCF TTM 1.14b)
Total Stockholder Equity = 10.38b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.64% (Net Income 1.48b / Total Assets 16.07b)
RoE = 14.26% (Net Income TTM 1.48b / Total Stockholder Equity 10.38b)
RoCE = 12.07% (EBIT 1.38b / Capital Employed (Equity 10.38b + L.T.Debt 1.07b))
RoIC = 9.37% (NOPAT 1.16b / Invested Capital 12.41b)
WACC = 8.51% (E(53.07b)/V(55.35b) * Re(8.84%) + D(2.28b)/V(55.35b) * Rd(1.00%) * (1-Tc(0.16)))
Discount Rate = 8.84% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.31%
[DCF Debug] Terminal Value 79.38% ; FCFF base≈1.37b ; Y1≈1.66b ; Y5≈2.72b
Fair Price DCF = 173.7 (EV 41.82b - Net Debt 1.83b = Equity 39.99b / Shares 230.2m; r=8.51% [WACC]; 5y FCF grow 22.85% → 2.90% )
EPS Correlation: 79.18 | EPS CAGR: 7.26% | SUE: 0.27 | # QB: 0
Revenue Correlation: 94.28 | Revenue CAGR: 8.76% | SUE: 1.08 | # QB: 3
EPS next Quarter (2026-03-31): EPS=1.90 | Chg30d=-0.000 | Revisions Net=+4 | Analysts=15
EPS current Year (2026-12-31): EPS=8.04 | Chg30d=+0.067 | Revisions Net=+5 | Growth EPS=+8.3% | Growth Revenue=+7.7%
EPS next Year (2027-12-31): EPS=8.70 | Chg30d=+0.070 | Revisions Net=+1 | Growth EPS=+8.1% | Growth Revenue=+5.9%